BR9606768A - Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra - Google Patents

Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra

Info

Publication number
BR9606768A
BR9606768A BR9606768A BR9606768A BR9606768A BR 9606768 A BR9606768 A BR 9606768A BR 9606768 A BR9606768 A BR 9606768A BR 9606768 A BR9606768 A BR 9606768A BR 9606768 A BR9606768 A BR 9606768A
Authority
BR
Brazil
Prior art keywords
valacyclovir hydrochloride
human
treatment
production
viral infection
Prior art date
Application number
BR9606768A
Other languages
English (en)
Portuguese (pt)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnikie
William Bayne Grubb
Gregory Allan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9606768(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of BR9606768A publication Critical patent/BR9606768A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9606768A 1995-01-20 1996-01-19 Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra BR9606768A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (1)

Publication Number Publication Date
BR9606768A true BR9606768A (pt) 1997-12-30

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9606768A BR9606768A (pt) 1995-01-20 1996-01-19 Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra

Country Status (40)

Country Link
US (1) US6107302A (en:Method)
EP (1) EP0804436B1 (en:Method)
JP (1) JP3176633B2 (en:Method)
KR (1) KR100376074B1 (en:Method)
CN (1) CN1049893C (en:Method)
AP (1) AP662A (en:Method)
AR (1) AR002270A1 (en:Method)
AT (1) ATE302777T1 (en:Method)
AU (1) AU702794B2 (en:Method)
BG (1) BG63393B1 (en:Method)
BR (1) BR9606768A (en:Method)
CA (1) CA2210799C (en:Method)
CY (1) CY2531B1 (en:Method)
CZ (1) CZ297065B6 (en:Method)
DE (1) DE69635106T2 (en:Method)
DK (1) DK0804436T3 (en:Method)
EA (1) EA000364B1 (en:Method)
EE (1) EE03528B1 (en:Method)
ES (1) ES2248806T3 (en:Method)
FI (1) FI973063L (en:Method)
GB (1) GB9501178D0 (en:Method)
GE (1) GEP20001940B (en:Method)
HR (1) HRP960024B1 (en:Method)
HU (1) HU222993B1 (en:Method)
IL (1) IL116831A (en:Method)
IN (1) IN182468B (en:Method)
IS (1) IS2268B (en:Method)
NO (1) NO315558B1 (en:Method)
NZ (1) NZ298851A (en:Method)
OA (1) OA10499A (en:Method)
PL (1) PL182175B1 (en:Method)
RO (1) RO118693B1 (en:Method)
RS (1) RS49518B (en:Method)
SI (1) SI0804436T1 (en:Method)
SK (1) SK285329B6 (en:Method)
TR (1) TR199700656T1 (en:Method)
UA (1) UA46001C2 (en:Method)
UY (1) UY25779A1 (en:Method)
WO (1) WO1996022291A1 (en:Method)
ZA (1) ZA96449B (en:Method)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
EP0976750A4 (en) * 1997-01-17 2001-05-30 Ajinomoto Kk NEW Z-VALACYCLOVIR CRYSTALS
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
JP5043286B2 (ja) * 2001-09-07 2012-10-10 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビル塩酸塩の結晶型
CA2465420A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CN1307177C (zh) * 2001-11-14 2007-03-28 特瓦制药工业有限公司 伐昔洛韦的合成与纯化
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
CA2527708A1 (en) 2003-06-02 2005-01-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
MXPA06008197A (es) * 2004-01-21 2007-04-02 Teva Pharma Proceso para la preparacion de clorhidrato de valaciclovir.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP2008504255A (ja) * 2004-06-30 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド 結晶塩酸バラシクロビル中の残留アルコールを低減する方法
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
ES2802243T3 (es) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
SK96597A3 (en) 1998-02-04
SI0804436T1 (sl) 2006-02-28
FI973063A0 (fi) 1997-07-18
OA10499A (en) 2002-04-10
IS2268B (is) 2007-07-15
WO1996022291A1 (en) 1996-07-25
CY2531B1 (en) 2006-04-12
AP662A (en) 1998-08-19
UA46001C2 (uk) 2002-05-15
EE03528B1 (et) 2001-10-15
NO973326D0 (no) 1997-07-18
EE9700175A (et) 1998-02-16
HUP9801836A3 (en) 1999-06-28
RO118693B1 (ro) 2003-09-30
AR002270A1 (es) 1998-03-11
IS4527A (is) 1997-07-15
IL116831A (en) 1998-10-30
CA2210799A1 (en) 1996-07-25
EA199700124A1 (ru) 1997-12-30
UY25779A1 (es) 2000-08-21
HRP960024B1 (en) 2005-08-31
AP9701058A0 (en) 1997-10-31
CA2210799C (en) 2008-06-10
HU222993B1 (hu) 2004-01-28
EA000364B1 (ru) 1999-06-24
MX9705462A (es) 1997-10-31
DK0804436T3 (da) 2005-12-27
TR199700656T1 (xx) 1998-03-21
SK285329B6 (sk) 2006-11-03
AU4453996A (en) 1996-08-07
CZ229497A3 (en) 1997-12-17
ATE302777T1 (de) 2005-09-15
PL321326A1 (en) 1997-12-08
HUP9801836A2 (hu) 1999-05-28
JP3176633B2 (ja) 2001-06-18
KR100376074B1 (ko) 2003-06-02
US6107302A (en) 2000-08-22
FI973063A7 (fi) 1997-09-18
DE69635106T2 (de) 2006-06-08
KR19980701525A (ko) 1998-05-15
ZA96449B (en) 1996-08-07
AU702794B2 (en) 1999-03-04
EP0804436B1 (en) 2005-08-24
ES2248806T3 (es) 2006-03-16
EP0804436A1 (en) 1997-11-05
BG101833A (bg) 1998-04-30
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
CN1179159A (zh) 1998-04-15
YU3396A (sh) 1998-12-23
DE69635106D1 (de) 2005-09-29
JPH11503718A (ja) 1999-03-30
FI973063L (fi) 1997-09-18
IL116831A0 (en) 1996-05-14
NZ298851A (en) 1999-01-28
CZ297065B6 (cs) 2006-08-16
IN182468B (en:Method) 1999-04-17
NO315558B1 (no) 2003-09-22
RS49518B (sr) 2006-10-27
NO973326L (no) 1997-09-16
GB9501178D0 (en) 1995-03-08
HRP960024A2 (en) 1997-10-31
PL182175B1 (pl) 2001-11-30
GEP20001940B (en) 2000-02-05

Similar Documents

Publication Publication Date Title
BR9606768A (pt) Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra
PT737199E (pt) Processo de preparacao de compostos de silicio biologicamente activos sob a forma concentrada
BR9101203A (pt) Artigo para tratamento de superficie e processo para sua fabricacao
PT92487A (pt) Processo para a preparacao de derivados de peptidos
PT96321A (pt) Processo para a preparacao de nucleosidos de purina
BR9107115A (pt) Processo para a preparacao continua de sulfatos de glicerideos parciais
FI953981A7 (fi) 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi
BR9406750A (pt) Processo para a fabricaçao de artigo ferramental mestre para replicaçao e artigo obtido
BR9205517A (pt) Processo para a preparacao continua de mosto e processo para preparar cerveja
BR9708533A (pt) Limitado retrorreflexivo artigo e processo para produzir um limitado retrorreflexivo
BR8803368A (pt) Processo para fabricar paredes laterais de lata em forma de troncos piramidas e equipamento para executar o processo
BR8903681A (pt) Processo para fabricar um artigo de limpeza e respectivo artigo de limpeza
BR9402087A (pt) Processo para a produção de isocianatos puros e utilização
BR9004421A (pt) Composicoes anti-estaticas e amaciantes de tecidos e processo para amaciar e prover um acabamento anti-estatico a tecidos
BR9406737A (pt) Instrumento cirúrgico a processo para remover tumores neurológicos
BR8800841A (pt) Laminador de cilindros axialmente deslocaveis e processo de regulagem de perfil de cilindro axialmente deslocaveis em um laminador
BR9303876A (pt) Processo para a preparacao de pirrol-(2,3-d)-pirimidinas substituidas na posicao 5 e composto obtido
BR9303403A (pt) Processo para produzir um artigo de borracha e artigo de borracha
BR9100196A (pt) Composicao herbicida e processo para produzir derivados de uracil
BR9005438A (pt) Poliaminas e seu processo de preparacao
BR9507494A (pt) Processo para a preparação de famciclovi de 2-amino-6-cloro purina e processo para a preparação de penciclovi de 2-amino-6- cloro purina
EE9600020A (et) 9-asendatud 2-(2-n-alkoksüfenüül)puriin-6-oonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
BR8806375A (pt) Processo para produzir fluoreto de titanio
PT93691A (pt) Processo para a preparacao de metil-nucleosidos 3'-substituidos com accao antiviral
BR9002746A (pt) Processo para a producao de cloreto de magnesio para uso na producao de magnesio metalico

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: NATURE S PLUS FARMACEUTICA LTDA.